Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment

Hongge Liang
Xiaoyan Liu
Mengzhao Wang

Department of Respiratory Medicine, Peking Union Medical College Hospital, Dongcheng District, Beijing 100730, China

Abstract: In recent years, targeted therapy and immunotherapy have played important roles in the treatment of patients with non-small-cell lung cancer (NSCLC). Drugs that target epidermal growth factor receptor (EGFR) mutations (e.g., gefitinib, erlotinib, icotinib, and osimertinib) are among the most commonly used targeted therapies. Afatinib is an irreversible second-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI), and the LUX-Lung 3 trial demonstrated the superiority of afatinib to cisplatin and pemetrexed in the frontline treatment of treatment-naïve patients with advanced EGFR mutation adenocarcinoma of the lung. Although these drugs show significant therapeutic efficacy, most patients invariably experience disease progression resulting in death. Immunotherapy targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) has now been approved for the first-line treatment of patients with advanced NSCLC. These can produce sustained clinical responses by reversing negative regulators of T-cell function; however, immunotherapy response rates remain low, and only a few patients ultimately benefit from this approach. Here, we discuss the potential of EGFR-TKIs for inducing antitumor immunity and the feasibility of their combination with immunotherapy (including PD-1/PD-L1 inhibitors) in NSCLC patients and the associated challenges for clinical application.

Keywords: non-small cell lung cancer, epidermal growth factor receptor-tyrosine kinase inhibitors, immunotherapy

Introduction

Lung cancer is the main cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases, is often diagnosed at a late stage and has a poor prognosis.1 EGFR is a member of the erythroblastosis oncogene B (ErbB)/human EGFR (HER) family. The family includes four tyrosine kinase receptors in humans: HER1 (EGFR/ErbBl); HER2 (Neu/ErbB2); HER3 (ErbB3); and HER4 (ErbB4).2 After EGFR binds to its ligand (EGF or transforming growth factor-α), the receptor is phosphorylated, forms a dimer, activates the downstream signaling pathway, and transmits signals to the nucleus via Ras-Raf-MEK and P13K/Akt pathways; these control cell proliferation, differentiation, apoptosis, invasion, and angiogenesis.3,4 EGFR is overexpressed in many tumors, such as those present in patients with lung cancer, colon cancer, stomach cancer, pancreatic cancer, bladder cancer, prostate cancer, ovarian cancer, and head and neck cancer.3,6 The abnormal activation of EGFR in tumor cells is currently thought to involve the following three mechanisms: 1) overexpression of nonligand-dependent EGFR; 2) point or deletion mutation of the gene encoding the EGFR tyrosine kinase activation domain; 3) tumor cell overexpression of transforming growth factor-α, which activates the EGFR.3,7–10
Tyrosine kinase inhibitors (TKIs) can significantly improve clinical outcomes in patients with NSCLC associated with EGFR mutations or anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 rearrangements. However, these genetic changes only occur in a subset of NSCLC patients; even if the treatments are initially effective in these patients, the tumors will inevitably develop resistance and the resultant disease progression will ultimately require the use of standard chemotherapy. First-generation (gefitinib and erlotinib) and second-generation (afatinib) EGFR-TKIs have shown advantages over platinum-based chemotherapy in NSCLC patients with EGFR mutations, producing higher response rates (RRs) and longer periods of progression-free survival (PFS). Dacomitinib is another second-generation EGFR-TKI that was reported to show significant improvement in overall survival (OS) in a Phase III randomized study compared with a standard-of-care TKI (95% CI, 0.582–0.993; two-sided P=0.044). However, the majority of patients treated with EGFR-TKIs eventually develop acquired resistance. Therefore, new treatment strategies for patients with NSCLC are urgently needed.

Immunotherapy provides another important treatment for NSCLC. In particular, complete activation of T cells is regulated by a “dual-signal” system. The first signal involves T-cell recognition of antigen and is derived from the specific binding of the T-cell receptor to the major histocompatibility complex. The second signal is mediated by the interaction of a costimulatory molecule expressed by the antigen-presenting cell, with the corresponding receptor on the T cell. In addition, there are also negative costimulatory molecules that limit T-cell stimulation. These molecules act via the cytotoxic T-lymphocyte-associated antigen-4-B7 (CTLA4-B7) pathway and the programmed cell death protein-1 (PD-1)/programmed cell death protein-ligand 1 (PD-L1) pathway. PD-1 (CD279) is an important immunoinhibitory checkpoint. It can inhibit the activation of T cells and the production of cytokines by binding to its two ligands, PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273), and plays an important role in maintaining peripheral tolerance. Tumor cells and the tumor microenvironment can escape the immune system by upregulating PD-L1 expression and binding to PD-1 on the surface of tumor-specific CD8+ T cells to limit the host’s immune response. At present, the most widely studied and used immunomodulatory checkpoint inhibitors include monoclonal antibodies raised against CTLA-4, PD-1, and PD-L1; these can reactivate the T-cell-mediated immune response to the tumor by suppressing immune checkpoints and thereby produce antitumor effects. Blockade of the PD-1/PD-L1 signaling pathway using monoclonal antibodies raised against PD-1/PD-L1 has shown excellent antitumor efficacy in a variety of solid tumors. To date, multiple anti-PD-1/PD-L1 antibodies have been approved by the Food and Drug Administration for first- and second-line treatment of patients with advanced NSCLC and have been shown to significantly improve clinical prognosis. For example, a PD-1 antibody (pembrolizumab) in combination with carboplatin and pemetrexed was approved for first-line combination therapy as well as for first-line treatment of metastatic nonsquamous cell NSCLC. However, immunotherapy is only effective for a small number of patients, and some patients who respond initially show a subsequent rapid disease progression. Therefore, a key challenge in lung cancer research is the discovery of prognostic biomarkers to guide the selection of patients most likely to benefit from this treatment; this requires detailed elucidation of the mechanisms underlying the interactions between tumors and immune cells.

The NSCLC mutation load can affect the tumor immunogenicity. Thus, targeted therapy can enhance the antitumor immune responses by releasing new antigens; this provides a theoretical basis for immunotherapy combined with targeted therapy. At present, immunotherapy combined with targeted therapy in NSCLC patients is still at an immature phase, and its effectiveness and safety have mainly been assessed by preclinical studies and early clinical trials. In this review, we summarize these early findings relating to the use of immunotherapy and EGFR-TKIs for the treatment of advanced NSCLC. This overview highlights both the progress made in this field to date and the remaining challenges.

Preclinical studies of EGFR-TKIs plus immunotherapy in NSCLC

Preclinical studies have shown that activation of the EGFR pathway can upregulate the expression of PD-1, PD-L1, and CTLA-4 through p-ERK1/2p-c-Jun, leading to the apoptosis of T cells in tumor microenvironment; this mediates the escape of tumor cells from the host immune response, leading to a state of immunosuppression. Using a murine model, Akbay et al found that PD-1 expression was upregulated in an EGFR-mutant cell line, while anti-PD-1 treatment resulted in a reduced tumor mass and prolonged mouse survival. Azuma et al used immunohistochemistry to analyze the expression of PD-L1 in 164 surgically resected NSCLC specimens, and multivariate analysis showed that EGFR mutations and adenocarcinoma were independent factors contributing to the increase of PD-L1 expression.
EGFR-TKIs not only target and kill the tumor directly but can also enhance the immune system response. Treatment of EGFR-mutant NSCLC cell lines with EGFR-TKIs reduced the expression of PD-1 and PD-L1 by inhibiting nuclear factor-kappa B (NF-κB) signaling. In addition, the EGFR inhibitor gefitinib enhanced the antigenicity of cancer cells by restoring major histocompatibility class 1 expression, and both gefitinib and erlotinib promoted the recognition and elimination of tumors by normal killer cells stimulated by NKG2D ligand in vitro or in immunocompetent host cancer cells. Table 1 summarizes the preclinical studies of the use of EGFR-TKIs plus immunotherapy in NSCLC.

These studies provide a theoretical basis for treatment using EGFR-TKIs in combination with immunotherapy in order to improve clinical outcomes in patients with NSCLC tumors harboring EGFR mutations, accompanied by upregulation of PD-L1 expression.

Clinical trials of EGFR-TKIs plus immunotherapy in NSCLC

Despite the potential of EGFR-TKIs and immunotherapy to suppress tumor growth and improve survival in vitro or in animal models, in practice, EGFR-mutant NSCLC is often associated with a lack of tumor-infiltrating lymphocytes; therefore, clinical trials have begun to examine the combined effects of EGFR-TKIs and an immunosuppressive agent; these are summarized in Table 2.

The randomized Phase III clinical study, OAK, analyzed 1,225 patients with locally advanced or metastatic NSCLC who had failed platinum-based chemotherapy. The primary efficacy analysis included the first 850 of these 1,225 enrolled patients. The patients were randomly assigned (1:1) to receive either atezolizumab 1,200 mg (n=425) or docetaxel 75 mg/m² (n=425) intravenously every 3 weeks. The primary endpoint was OS in the intention-to-treat and PD-L1 expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumor cells or tumor-infiltrating immune cells). The results showed that in the intention-to-treat population, the OS of patients treated with atezolizumab was significantly longer than that of those receiving docetaxel (13.8 vs 9.6 months, HR 0.73 [95% CI, 0.62–0.87], P=0.0003). In the TC1/2/3 or IC1/2/3 population, OS was also longer with atezolizumab (n=241) than that with docetaxel (n=222; 15.7 vs 10.3 months; HR 0.74 [95% CI, 0.58–0.93]; P=0.0102).

A meta-analysis of three clinical trials (CheckMate 057, KEYNOTE-010, and POPLAR studies) investigating combined immunotherapy and chemotherapy for patients with advanced NSCLC, including patients with EGFR-mutated NSCLC treated with EGFR-TKI-targeted therapy, showed that patients with EGFR mutations did not obtain a survival benefit from treatment with a PD-L1/PD-L1 monoclonal antibody compared with those treated with docetaxel.

A Phase I clinical trial (NCT02013219) reported the preliminary results of erlotinib plus atezolizumab treatment in patients with NSCLC. The safety phase included patients with locally advanced or metastatic NSCLC, and the extension phase included patients with EGFR mutations who did not receive TKIs. Toward the end of the trial, 28 patients (eight in the safety phase and 20 in the extension phase) were evaluated for safety and efficacy. This study found that 39% of the patients had grade 3–4 adverse reactions, mainly fever and elevated alanine aminotransferase levels, although there were no reports of interstitial pneumonia interstitial lung disease.
In terms of clinical efficacy, the objective response rate (ORR) reached 75% with a median duration of 9.7 months. This trial showed that combination therapy can lead to a significant increase in adverse reactions in the absence of substantial improvements in ORR or OS.50 Another Phase I clinical trial (NCT02088112) evaluated the treatment of patients with NSCLC using gefitinib and durvalumab. By the end of the trial, 20 EGFR-TKI-naïve patients with EGFR-mutated NSCLC were included in the expansion phase; half of these received both durvalumab (10 mg/kg once every 2 weeks) and gefitinib (250 mg/day) (group 1), while the other half received gefitinib monotherapy for 28 days, followed by combined gefitinib and durvalumab treatment (group 2). Due to extensive grade 3–4 adverse reactions, four patients in group 2 discontinued treatment; three patients had elevated activities of alanine aminotransferase/aspartate aminotransferase and one patient developed ILD. In terms of clinical efficacy, the ORRs of patients in groups 1 and 2 were 77.8% and 80%, respectively.51 As part of the CheckMate 012 study, the efficacy of erlotinib combined with nivolumab was evaluated in 21 patients with EGFR-mutated NSCLC; 20 patients received erlotinib and one patient did not receive EGFR-TKI therapy.52 The treatment regimen was nivolumab (3 mg/kg, once every 2 weeks)+erlotinib (150 mg, once a day) until disease progression or intolerable toxicity occurred. The most common side effects included rash, fatigue, paronychia, diarrhea, and cracked skin. Grade 3 toxicity occurred in 19% of patients, but no grade 4 toxicity was reported. In terms of clinical efficacy, the ORR was 19%, PFS was 51% at 24 weeks, and OS was 64% at 18 months. In addition, three of the 20 patients treated with EGFR-TKIs achieved partial remission, with a median time to remission of 60.1 weeks. Two repeat biopsies of patients with T790M-negative tumors showed a PFS of 61 weeks and ≥108 weeks. One patient who had not received treatment with EGFR-TKIs reached partial remission at the time of the report and continued the treatment for 72.3 weeks. Owing to treatment-related adverse events (grade 3 aspartate aminotransferase elevation and grade 2 nephritis), two patients discontinued the treatment.

The Phase Ib TATTON study evaluated combination treatments with osimertinib and MEDI4736, AZD6094, or selumetinib in EGFR active mutant lung cancer and also determined the efficacy of axitinib in combination with the anti-PD-L1 antibody durvalumab.53 A total of 34 patients were assigned to the EGFR-TKI-treated group (23 cases, increasing dose phase, group A) and EGFR-TKI initial treatment group (11 cases, extended phase, group B). The treatment regimen was osimertinib (80 mg once a day)+durvalumab (3 mg/kg or 10 mg/kg once every 2 weeks). The ORR for T790M-positive and T790M-negative patients treated with EGFR-TKIs was 67% and 21%, respectively.

**Table 2 Clinical trials of immune checkpoint inhibitors in combination with EGFR-TKIs in advanced NSCLC**

<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Patients</th>
<th>Targeted agent</th>
<th>Immunotherapy</th>
<th>Phase</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02088112</td>
<td>LA/stage IV TKI-naive EGFR-mutated NSCLC</td>
<td>Gefitinib</td>
<td>Durvalumab</td>
<td>I</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT02040064i/GEFTREM</td>
<td>LA/stage IV TKI-pretreated EGFR-mutated NSCLC</td>
<td>Gefitinib</td>
<td>Tremelimumab</td>
<td>I</td>
<td>Completed</td>
</tr>
<tr>
<td>NCT02574078i/CheckMate 370</td>
<td>Newly diagnosed/maintenance LA/stage IV NSCLC</td>
<td>Erlotinib</td>
<td>Nivolumab</td>
<td>I/II</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT01998126</td>
<td>Stages II–IV TKI-naive or TKI treated for &lt;6 months EGFR- or ALK-mutated NSCLC</td>
<td>Erlotinib</td>
<td>Nivolumab/ ipilimumab</td>
<td>I</td>
<td>Completed</td>
</tr>
<tr>
<td>NCT01454102i/CheckMate 012</td>
<td>Newly diagnosed or pretreated stage IIIB/IV NSCLC</td>
<td>Erlotinib</td>
<td>Nivolumab</td>
<td>I</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT02013219</td>
<td>LA/stage IV TKI-naive and treatment-naive ALK-positive NSCLC</td>
<td>Erlotinib</td>
<td>Atezolizumab</td>
<td>I</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT02039674i/KEYNOTE-021</td>
<td>Newly diagnosed stage IIIB/IV NSCLC, progression &gt;1 year after adjuvant therapy for stages I–III A NSCLC</td>
<td>Erlotinib/gefitinib</td>
<td>Pembrolizumab</td>
<td>I/II</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT02630186</td>
<td>Patients with activating EGFR mutation-positive (EGR) advanced or metastatic NSCLC</td>
<td>Rociletinib</td>
<td>Atezolizumab</td>
<td>I/II</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT03157089i/LUX-Lung IO</td>
<td>Pretreated stage IIIB/IV squamous NSCLC</td>
<td>Afatinib</td>
<td>Pembrolizumab</td>
<td>II</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02364609</td>
<td>LA/stage IV recurrent erlotinib-resistant EGFR-mutated NSCLC</td>
<td>Afatinib</td>
<td>Pembrolizumab</td>
<td>I</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02143466</td>
<td>EGFR-mutated NSCLC who have progressed following therapy with an EGFR-TKI</td>
<td>Osimertinib</td>
<td>Durvalumab</td>
<td>I</td>
<td>Terminated*</td>
</tr>
</tbody>
</table>

**Note:** Due to an increased incidence of interstitial pneumonia-like events (interstitial lung disease/pneumonitis).

**Abbreviations:** ALK, anaplastic lymphoma kinase; LA, locally advanced; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor.
whereas that for patients who did not receive EGFR-TKIs was 70%. However, this combination therapy was associated with a high incidence of ILD, which occurred in 38% (13/34) of patients overall (26% [6/23] in group A and 64% [7/11] in group B). In contrast, the incidence of ILD associated with osimertinib and durvalumab was only 2%–3% and <2%, respectively. The median time for ILD to occur was 69 days. Five of the 13 patients who developed ILD had grade 3/4, but there were no deaths, and most were alleviated using high-dose corticosteroids and discontinuation of the target drug. Because the underlying mechanisms associated with this high incidence of ILD remain unknown, recruitment has stopped for this arm of this trial. Similarly, a Phase III clinical trial CAUREL (NCT02454933) assessing the effects of durvalumab in combination with osimertinib or osimertinib alone in T790M-positive NSCLC patients after treatment with EGFR-TKIs has also been suspended. Oshima et al analyzed the incidence of EGFR-TKI-associated interstitial pneumonitis (IP) in patients receiving or not receiving nivolumab treatment. The results showed that the incidence of IP was 4.8% (985/20,516) in all the patients, with incidences of 4.59% (265/5,777) and 25.7% (18/70) in those treated with EGFR-TKI or both EGFR-TKI and nivolumab, respectively. The adjusted odds ratio for an interaction between EGFR-TKI and nivolumab was 4.31 (95% CI, 2.37–7.86; P<0.001), suggesting a higher proportion of reports of IP for nivolumab in combination with EGFR-TKI vs treatment with either drug alone. Haratani et al reported the results of a study of 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab after progressing to EGFR-TKIs. The T790M-negative patients had a longer PFS (2.1 months) than the T790M-positive patients (1.3 months) and also had a higher proportion of tumors with a PD-L1 level of <10% or ≥50% than that of the T790M-positive patients, along with higher CD8+ tumor infiltration and a greater tumor mutation load.

Potential factors affecting the success of combined EGFR-TKIs and immunotherapy

The clinical studies conducted to date have shown that the combination of EGFR-TKIs with immunity checkpoint inhibitors does not have a synergistic tumor cell-killing effect. The tumor mutation load, epithelial–mesenchymal transition, and transforming growth factor-β all affect tumor immunogenicity. Moreover, PD-L1 expression alone does not accurately predict the prognosis of PD-1/PD-L1 monoclonal antibody therapy in patients with NSCLC. Prognosis is also associated with smoking history and the tumor mutation burden. Because the incidence of tumor mutation in smokers is 10 times higher than in nonsmokers, smoking history is strongly related to the clinical prognosis of NSCLC immunotherapy. However, most patients carrying EGFR gene mutations are those that smoked mildly or are nonsmokers, with a low tumor mutation burden. Exome sequencing analysis showed that EGFR-mutated NSCLC patients had a low mutation load, which may lead to a low RR to immunotherapy. Moreover, only a small proportion of patients with EGFR mutation and ALK rearrangement have both positive PD-L1 expression and high levels of CD8+ tumor-infiltrating lymphocytes, suggesting that the lack of an inflammatory microenvironment may limit the efficacy of PD-1/PD-L1 monoclonal antibodies.

PD-L1 can be induced by oncogenic signals and can also be upregulated by interferon-gamma (INFG) in a STAT-1 and NF-κB-dependent manner. A recent study evaluating INFG levels in pretreatment tumor samples from patients with advanced NSCLC showed that intermediate and high levels of INFG microRNA expression correlated with longer PFS and OS and higher disease control rates with PD-1 monoclonal antibody treatment, even when PD-L1 expression was low. In contrast, low levels of INFG were correlated with poor prognosis. Another study showed that in EGFR-mutant tumor samples, overexpression of the immunosuppressive molecule CD73 was associated with low INFG expression, which may be associated with the poor therapeutic efficacy of PD-1/PD-L1 antibodies in this group of patients. Overall, EGFR-mutant NSCLC-mediated immune escape appears to mainly occur by upregulating PD-L1 expression; thus, EGFR-TKIs and PD-1 monoclonal antibodies may have similar but not synergistic effects in targeting this mechanism.

Conclusion and future prospects

This review summarizes the potential benefits and problems associated with the combined use of EGFR-TKIs and immunotherapy in patients with NSCLC. In preclinical studies, EGFR signaling pathways induced the expression of PD-L1 and other immunosuppressive factors, suggesting that EGFR oncogenes effectively remodel the immune microenvironment. Several early clinical studies have also confirmed the efficacy of immunotherapy in patients with EGFR-mutant NSCLC; however, grade 3–4 adverse events such as elevated ILD incidence and alanine aminotransferase/aspartate aminotransferase levels resulted in treatment failure. Several large randomized Phase III clinical trials have not demonstrated
a clinical benefit of PD-1/PD-L1 monoclonal antibodies in patients with EGFR-mutant NSCLC; this may be due to a lower tumor mutation burden, fewer CD8\(^+\) tumor-infiltrating cells, and lower expression of INF\(\gamma\) in these cases.

Nanotechnology is a comprehensive platform that has the potential to significantly improve cancer diagnosis and treatment while reducing toxicity. Nanoparticles, which are generally derived from polymers, lipids, or metals, can be coupled with a therapeutic drug and used to target tumors by exploiting their biophysical differences from normal tissue; these include hypoxia and an acidic pH. Nanoparticles can also incorporate specific targeting ligands designed to bind with receptors that are overexpressed by tumor cells or stromal cells, facilitating drug delivery and release at the site of action.\(^7\) Therefore, nanomedicines provide high levels of control, biocompatibility, versatility, and surface area to volume ratios;\(^74,75\) they provide opportunities to target tumors, to release the drug cargo specifically in the tumor microenvironment, and to increase the drug circulation half-life.\(^76,77\) Wang et al also discussed the use of nanomaterials as gene delivery systems.\(^80\) In addition, nanomaterials can be designed to provide more complex therapeutic agents, such as codelivery of antitumor drugs with antiangiogenic antibodies or peptides, or other immunotherapeutic antibodies.\(^81-85\) Therefore, the treatment of patients with NSCLC may be further improved by coupling commonly used EGFR-TKIs and immunity checkpoint inhibitors to nanoparticles.

Research relating to the use of EGFR-TKIs combined with immunotherapy in the treatment of NSCLC is still at an early stage. Thus, further efforts are needed to assess the different drugs, dosages, administration sequences, and side effects associated with this type of combination therapy.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


